---
title: "MercadoLibre hits 52-week low"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306221606.md"
description: "MercadoLibre fell 0.61% to US$1347.17. Down 11.96% over ten sessions and down 33.12% YTD."
datetime: "2026-11-20T05:28:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306221606.md)
  - [en](https://longbridge.com/en/news/306221606.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306221606.md)
generator: "portal-rs"
---

# MercadoLibre hits 52-week low

MercadoLibre (MELI.US) slipped less than **1%** in overnight trading to **$1,347.17**, hitting a 52-week low.

The stock is down 11.96% over the past ten sessions and down 33.12% year to date. It sits 42.48% below its 52-week high of US$2342.00. Volume was 3.20 times its average.

The Nasdaq Composite is down 5.86% over the past five sessions and up 2.74% year to date.

BofA Global Research cut its price target on the stock to $2,000 from $2,400.

The company reported third-quarter results on Nov. 4, with total revenue of $10.75 billion, up 45% year-over-year. Operating income came in at $680 million, about 7% below market expectations, while the operating margin narrowed 40 basis points sequentially to 6.3%, mainly due to increased spending on logistics, marketing and AI. Morgan Stanley had previously lowered its price target to $2,350 after margins missed estimates.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [MELI.US](https://longbridge.com/en/quote/MELI.US.md)

## Related News & Research

- [Michael Burry Donates Alphabet Shares, Then Buys the Software Stock Wall Street Fears Most](https://longbridge.com/en/news/305856051.md)
- [Michael Burry boosts Adobe stake, exits Oracle, Caterpillar puts](https://longbridge.com/en/news/305800992.md)
- [What Is Booking Holdings (BKNG) Really Building With Its New AI Travel Push?](https://longbridge.com/en/news/306318265.md)
- [AI solves 167-year-old maths problem, Anthropic researcher claims](https://longbridge.com/en/news/306318851.md)
- [CAPR: FDA issued a CRL for Deramiocel, citing insufficient evidence of effectiveness](https://longbridge.com/en/news/306366333.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**